Takeda Pharmaceutical (TAK) Cash & Current Investments (2017 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Cash & Current Investments of $5.8 billion for Q2 2026, up 22.08% year-over-year from $4.7 billion in Q2 2025, and down 12.15% quarter-over-quarter from $6.6 billion in Q1 2026.
Takeda Pharmaceutical (TAK) Cash & Current Investments (2017 - 2026) Analysis & Trends
Takeda Pharmaceutical's Cash & Current Investments history runs 10 years deep, the most recent figure standing at $5.8 billion for Q2 2026.
- In Q2 2026, Cash & Current Investments rose 22.08% year-over-year to $5.8 billion; the TTM figure through Jun 2026 stood at $5.8 billion (up 22.08% YoY), while the FY2026 annual figure was $6.9 billion, up 158.23% from the prior year.
- Cash & Current Investments for Q2 2026 stood at $5.8 billion, down from $6.6 billion in the prior quarter.
- The five-year high for Cash & Current Investments was $8.2 billion in Q3 2022, with the low at $2.7 billion in Q1 2025.
- The 5-year median for Cash & Current Investments is $6.2 billion (2024), against an average of $5.8 billion.
- The sharpest annual moves came in 2023 and 2026: Cash & Current Investments plunged 46.43% in 2023, then jumped 148.25% in 2026.
- Takeda Pharmaceutical's Cash & Current Investments stood at $6.8 billion in 2022, then sank by 44.46% to $3.8 billion in 2023, then surged by 55.37% to $5.9 billion in 2024, then climbed by 19.53% to $7.0 billion in 2025, then fell by 17.3% to $5.8 billion in 2026.
- Business Quant data shows TAK's Cash & Current Investments at $5.8 billion in Q2 2026, $6.6 billion in Q1 2026, and $7.0 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | 963.33 Mn |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 1.68 Bn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 5.80 Bn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 2.66 Bn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 389.80 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 164.00 Mn |
| 10 | Alkermes | 8.19 Bn | 7.53 Bn | 397.90 Mn | 656.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.80 Bn |
| Mar 31, 2026 | 6.60 Bn |
| Dec 31, 2025 | 7.01 Bn |
| Sep 30, 2025 | 7.11 Bn |
| Jun 30, 2025 | 4.75 Bn |
| Mar 31, 2025 | 2.66 Bn |
| Dec 31, 2024 | 5.87 Bn |
| Sep 30, 2024 | 7.51 Bn |
| Jun 30, 2024 | 7.48 Bn |
| Mar 31, 2024 | 3.19 Bn |
| Dec 31, 2023 | 3.77 Bn |
| Sep 30, 2023 | 4.37 Bn |
| Jun 30, 2023 | 4.45 Bn |
| Mar 31, 2023 | 4.19 Bn |
| Dec 31, 2022 | 6.80 Bn |
| Sep 30, 2022 | 8.16 Bn |
| Jun 30, 2022 | 7.20 Bn |
| Mar 31, 2022 | 7.53 Bn |
| Dec 31, 2021 | 8.40 Bn |
| Sep 30, 2021 | 7.67 Bn |